MT-act spun out from the Institute of Human Genetics and CNRS in Montpellier, leverages recent advances in understanding cytoskeleton stiffness and its influence on age-related diseases.
The founders, Dr. Siem van der Laan (CEO) and Dr. Khaled Hached (COO), based on their expertise in the field, identified the therapeutic potential of targeting microtubule-modifying enzymes that affect cytoskeleton rigidity, which are dysregulated in certain diseases. MT-act has developed a breakthrough drug discovery platform, MT-discover®, to identify small molecule drugs targeting these enzymes.
They recently published the results of a collaboration with UPenn in Science Translational Medicine, demonstrating therapeutic benefits with their lead compounds in an in vivo gold-standard preclinical model of HFpEF, as well as proof-of-mechanism in human cardiomyocytes from both failing and non-failing hearts.
The company is building a pipeline of programs targeting heart, neurodegenerative, and ophthalmological diseases.
We are pleased to welcome MT-act to our portfolio!
